Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice

(2009) Antonio Marchesoni et al.   Annals of the New York Academy of Sciences

The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents

(2009) M Boers   ANNALS OF THE RHEUMATIC DISEASES

A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals

(2009) M. Boers   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate: the gold standard without standardisation

(2009) J. Kay et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness of tumour necrosis factor   inhibitors in combination with either methotrexate or leflunomide

(2009) A Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

(2009) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clinical practice based on rheumatologists' preferences

(2009) Bruno Fautrel et al.   ARTHRITIS AND RHEUMATISM

Defining remission in rheumatoid arthritis: Results of an initial american college of rheumatology/european league against rheumatism consensus conference

(2009) Lilian H. D. van Tuyl et al.   ARTHRITIS AND RHEUMATISM

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

The use of data from early arthritis clinics for clinical research

(2009) Daniel Aletaha et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists

(2009) John D Isaacs   EXPERT OPINION ON BIOLOGICAL THERAPY

The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis

(2009) M. BLOM et al.   JOURNAL OF RHEUMATOLOGY

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

(2009) RF van Vollenhoven et al.   LANCET

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Prognostic factors in rheumatoid arthritis in the era of biologic agents

(2009) Alla Skapenko et al.   Nature Reviews Rheumatology

The Disease Activity Score and the EULAR Response Criteria

(2009) Jaap Fransen et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

(2009) M. Soubrier et al.   RHEUMATOLOGY

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

(2009) Andrea Rubbert-Roth et al.   ARTHRITIS RESEARCH & THERAPY

Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis

(2008) B Kuriya et al.   ANNALS OF THE RHEUMATIC DISEASES

Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial

(2008) L H D van Tuyl et al.   ANNALS OF THE RHEUMATIC DISEASES

Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?

(2008) B Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

(2008) J S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

(2008) D Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study

(2008) I Hafstrom et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial

(2008)   ARTHRITIS AND RHEUMATISM

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

(2008) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making

(2008) Annette H. M. van Der Helm-van Mil et al.   ARTHRITIS AND RHEUMATISM

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

(2008) Josef S Smolen et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis

(2007) P. Verschueren et al.   RHEUMATOLOGY